APAP 325 mg/Phenylephrine HCl 5 mg Tablets Bulk Container Recall
ULTRAtab Laboratories is recalling approximately 451,123 APAP 325 mg/Phenylephrine HCl 5 mg tablets in bulk containers due to CGMP deviations. The product was distributed to three distributors for further distribution as finished goods.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall with no reported illnesses or injuries. The hazard identified is a manufacturing practice deviation rather than a direct safety hazard with immediate health consequences. Class II recalls with no reported harm typically score 2 per the rubric.
Plain-English summary
ULTRAtab Laboratories, Inc., located in Highland, New York, is recalling APAP 325 mg/Phenylephrine HCl 5 mg tablets supplied in bulk containers. The affected product is identified by NDC 62959-135-00, with product code C135LA and bulk lot 19F077. Approximately 451,123 tablets are included in this recall.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified at the manufacturing facility. This is a voluntary recall initiated by the firm and was classified by the FDA as Class II on February 9, 2022.
The bulk product was distributed to three distributors, who may have further distributed finished products to other entities. Consumers or healthcare professionals who have received products from this recall should contact the recalling firm or their distributor for instructions regarding return or disposal. The recall was terminated on January 7, 2025.
The recalled product
- Product
- APAP 325 mg/Phenylephrine HCl, 5mg Tablets Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-135-00
- Manufacturer
- ULTRAtab Laboratories, Inc.
- Affected units
- 451,123
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Product Codes: C135LA Bulk Lots: 19F077
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 33 recalled by ULTRAtab Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 33 products in this recall →Related recalls
Same manufacturer · ULTRAtab Laboratories, Inc.
See all →- ModerateDBI Magnums Caffeine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateHPC Tablet Drug Recalled Due to CGMP Manufacturing Deviations
FDA (Drugs) · 2022-02-16
- ModerateMelatonin ER supplement recalled for manufacturing practice deviations
FDA (Food) · 2022-02-16
- ModerateDietary supplement melatonin recall due to manufacturing deviations
FDA (Food) · 2022-02-16
- Moderate
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls MYXREDLIN Insulin Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09